BioStock: SynAct Pharma’s CEO provides an update
SynAct Pharma has signed a contract with a CRO and aims to submit a Clinical Trial Application this quarter for the upcoming clinical phase IIb study with resomelagon. Furthermore, the company has conducted a capital raise of SEK 49 million, and the new board and management team are working to reduce costs.– Together, the new team is more focused and ready to move fast, says CEO Jeppe Øvlesen.Read the full article at biostock.se : https://www.biostock.se/en/2024/05/synact-pharmas-ceo-provides-an-update/ This is a press release from BioStock - Connecting